These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35248772)

  • 1. Targeting DNA Methyl Transferases with Decitabine in Cultured Meningiomas.
    Tatman PD; Wroblewski TH; Fringuello AR; Scherer SR; Foreman WB; Damek DM; Lillehei KO; Jensen RL; Youssef AS; Ormond DR; Graner MW
    World Neurosurg; 2022 Jun; 162():e99-e119. PubMed ID: 35248772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular predictors for decitabine efficacy in meningiomas - a pilot study.
    Spille DC; Thomas C; Wagner A; Grauer OM; Canisius J; Bunk EC; Stummer W; Eich HT; Paulus W; Senner V; Brokinkel B
    J Neurooncol; 2023 Aug; 164(1):97-105. PubMed ID: 37477823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas.
    Youngblood MW; Tran AN; Wang W; An S; Scholtens D; Zhang L; O'Shea K; Pokorny JL; Magill ST; Sachdev S; Lukas RV; Ahmed A; Unruh D; Walshon J; McCortney K; Wang Y; Baran A; Sahm F; Aldape K; Chandler JP; David James C; Heimberger AB; Horbinski C
    Neuro Oncol; 2023 Mar; 25(3):508-519. PubMed ID: 35976058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of decitabine-targeted oncogenes in meningiomas in vivo.
    Canisius J; Wagner A; Bunk EC; Spille DC; Stögbauer L; Grauer O; Hess K; Thomas C; Paulus W; Stummer W; Senner V; Brokinkel B
    Neurosurg Rev; 2022 Aug; 45(4):2767-2775. PubMed ID: 35445910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathodiagnostic parameters and evaluation of O⁶- methyl guanine methyl transferase gene promoter methylation in meningiomas.
    Jabini R; Moradi A; Afsharnezhad S; Ayatollahi H; Behravan J; Raziee HR; Mosaffa F
    Gene; 2014 Apr; 538(2):348-53. PubMed ID: 24398011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylation of O6-methyl guanine methyltransferase gene promoter in meningiomas--comparison between tumor grades I, II, and III.
    Larijani L; Madjd Z; Samadikuchaksaraei A; Younespour S; Zham H; Rakhshan A; Mohammadi F; Rahbari A; Moradi A
    Asian Pac J Cancer Prev; 2014; 15(1):33-8. PubMed ID: 24528051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features.
    Choudhury A; Chen WC; Lucas CG; Bayley JC; Harmanci AS; Maas SLN; Santagata S; Klisch T; Perry A; Bi WL; Sahm F; Patel AJ; Magill ST; Raleigh DR
    Neuro Oncol; 2023 Mar; 25(3):520-530. PubMed ID: 36227281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.
    Schrell UM; Rittig MG; Anders M; Kiesewetter F; Marschalek R; Koch UH; Fahlbusch R
    J Neurosurg; 1997 May; 86(5):845-52. PubMed ID: 9126901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation status of MGMT gene promoter in meningiomas.
    de Robles P; McIntyre J; Kalra S; Roldán G; Cairncross G; Forsyth P; Magliocco T; Hamilton M; Easaw J
    Cancer Genet Cytogenet; 2008 Nov; 187(1):25-7. PubMed ID: 18992637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis.
    Johnson MD; O'Connell MJ; Walter K
    BMC Complement Altern Med; 2013 Nov; 13():303. PubMed ID: 24188277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
    Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
    Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic changes underlie the aggressiveness of histologically benign meningiomas that recur.
    San-Miguel T; Navarro L; Megías J; Muñoz-Hidalgo L; Gil-Benso R; Roldán P; López-Ginés C; Cerdá-Nicolás M
    Hum Pathol; 2019 Feb; 84():105-114. PubMed ID: 30261191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific.
    Jun P; Hong C; Lal A; Wong JM; McDermott MW; Bollen AW; Plass C; Held WA; Smiraglia DJ; Costello JF
    Neuro Oncol; 2009 Aug; 11(4):414-22. PubMed ID: 19001526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation in the malignant transformation of meningiomas.
    Gao F; Shi L; Russin J; Zeng L; Chang X; He S; Chen TC; Giannotta SL; Weisenberger DJ; Zada G; Mack WJ; Wang K
    PLoS One; 2013; 8(1):e54114. PubMed ID: 23349797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YAP1-FAM118B Fusion Defines a Rare Subset of Childhood and Young Adulthood Meningiomas.
    Schieffer KM; Agarwal V; LaHaye S; Miller KE; Koboldt DC; Lichtenberg T; Leraas K; Brennan P; Kelly BJ; Crist E; Rusin J; Finlay JL; Osorio DS; Sribnick EA; Leonard JR; Feldman A; Orr BA; Serrano J; Vasudevaraja V; Snuderl M; White P; Magrini V; Wilson RK; Mardis ER; Boué DR; Cottrell CE
    Am J Surg Pathol; 2021 Mar; 45(3):329-340. PubMed ID: 33074854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biological determinations of meningioma progression and recurrence.
    Linsler S; Kraemer D; Driess C; Oertel J; Kammers K; Rahnenführer J; Ketter R; Urbschat S
    PLoS One; 2014; 9(4):e94987. PubMed ID: 24722350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
    Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
    Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Aberrant methylation of NF2, TIMP-3 and THBS1 genes and their diagnostic values in meningiomas].
    Gong J; Zhu SG; Wu CY; Li XG; Liu YG; Ren XH; Zhang Y
    Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(41):2889-92. PubMed ID: 23328233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation analysis of benign and atypical meningiomas: correlation between RUNX3 methylation and WHO grade.
    Majchrzak-Celińska A; Paluszczak J; Szalata M; Barciszewska AM; Nowak S; Baer-Dubowska W
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1593-601. PubMed ID: 25648363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.